Kadri Altundağ
- Oncology top 1%
- Pulmonary and Respiratory Medicine top 2%
- Cancer Research top 2%
- Molecular Biology top 10%
- Orthopedics and Sports Medicine top 1%
- Co-authors
- Sercan AksoyÖmer DızdarMehmet Alı Nahıt ŞendurYavuz ÖzışıkÇağatay ArslanTaner BabacanGabriel N. HortobágyiHakan Harputluoğlu
- Topics
- Breast Cancer Treatment Studies (64 papers)HER2/EGFR in Cancer Research (59 papers)Cancer Treatment and Pharmacology (56 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- TürkiyeUnited StatesIndia
In The Last Decade
Kadri Altundağ
234 papers receiving 3.7k citations
Peers
Comparison fields: 5 of 129
- Oncology 2.5k
- Pulmonary and Respiratory Medicine 915
- Cancer Research 748
- Molecular Biology 717
- Orthopedics and Sports Medicine 471
Countries citing papers authored by Kadri Altundağ
This map shows the geographic impact of Kadri Altundağ's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kadri Altundağ with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kadri Altundağ more than expected).
Fields of papers citing papers by Kadri Altundağ
This network shows the impact of papers produced by Kadri Altundağ. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kadri Altundağ. The network helps show where Kadri Altundağ may publish in the future.
Co-authorship network of co-authors of Kadri Altundağ
This figure shows the co-authorship network connecting the top 25 collaborators of Kadri Altundağ. A scholar is included among the top collaborators of Kadri Altundağ based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kadri Altundağ. Kadri Altundağ is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer. | 0 |
| 3 | Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey. | 3 |
| 4 | Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. | 0 |
| 5 | Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes. | 7 |
| 6 | Trastuzumab 1-year vs 9-week in early-stage HER2-positive, lymph node negative breast cancer patients. | 0 |
| 7 | Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer. | 9 |
| 8 | Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. | 7 |
| 9 | A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer. | 5 |
| 10 | Molecular subtypes in patients with inflammatory breast cancer; a single center experience. | 16 |
| 11 | Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis. | 2 |
| 12 | 2 | |
| 13 | Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer. | 5 |
| 14 | Impact of the obesity on lymph node status in operable breast cancer patients. | 9 |
| 15 | 6 | |
| 16 | Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. | 15 |
| 17 | 24 | |
| 18 | ABO and Rh blood groups frequency in women with HER2 positive breast cancer. | 6 |
| 19 | 7 | |
| 20 | 2 |
About Kadri Altundağ
Kadri Altundağ is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 251 papers that have together received 3.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (64 papers), HER2/EGFR in Cancer Research (59 papers) and Cancer Treatment and Pharmacology (56 papers). The work is most often cited by research in Oncology (2.5k citations), Orthopedics and Sports Medicine (471 citations) and Cancer Research (748 citations). Kadri Altundağ has collaborated with scholars based in Türkiye, United States and India. Frequent co-authors include Sercan Aksoy, Ömer Dızdar, Mehmet Alı Nahıt Şendur, Yavuz Özışık, Çağatay Arslan, Taner Babacan, Gabriel N. Hortobágyi, Hakan Harputluoğlu, Ali Sever and Ana O. Hoff. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.